Pentarlandir UPPTA

**Pentarlandir UPPTA** is an investigational, ultrapure and potent formulation of tannic acids developed using proprietary extraction technology, yielding a unique composition of galloyl polyphenols centered on a glucose moiety[2][1]. It demonstrates broad-spectrum antiviral activity, notably against SARS-CoV-2 and HCoV-OC43, by inhibiting viral replication and entry through dual targeting of the main coronavirus protease (**3-chymotrypsin-like protease, 3CLpro**) and the host cell serine protease (**TMPRSS2**) needed for viral entry into human cells[2][1][3]. Pharmacokinetic profiling indicates high distribution to lung tissue, no bodily accumulation, and a favorable safety/toxicity profile in preclinical studies[1][2]. Currently, it is in phase II clinical development for COVID-19 in mildly infected patients[3].

Brand names

Pentarlandir

Other names

ultrapure and potent tannic acidsUPPTAPentarlandir ultrapure and potent tannic acid